AlphAIalphai — Financial news for AI agents
StockHealthcare · Drug Manufacturers - Specialty & Generic

$ETON

Eton Pharmaceuticals, Inc.

Price · $ETONvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $ETON in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $ETON in the last 30 days.

Top stories · $ETONMore →
APR 15·MarketBeatMed

Eton Pharmaceuticals (NASDAQ:ETON) Sets New 1-Year High - Time to Buy?

Shares of Eton Pharmaceuticals (NASDAQ:ETON) recently reached a new 52-week high of $27.24, with a consensus price target of $39.33 from analysts who rate the stock as a "Moderate Buy." Despite missing EPS estimates in its latest quarterly results, the company surpassed revenue expectations and has seen increased institutional investment, with approximately 27.9% of shares held by institutions. This growing investor interest comes as several analysts have upgraded their ratings and raised price targets for the specialty pharmaceutical company.

MAR 31·MarketBeat

JPMorgan Chase & Co. Has $7.64 Million Stock Position in Eton Pharmaceuticals, Inc. $ETON

JPMorgan Chase & Co. increased its holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 44.9% during the third quarter, now owning 351,417 shares valued at approximately $7.64 million. Despite the company missing EPS estimates but beating revenue expectations, analyst sentiment is largely positive, with a "Moderate Buy" consensus rating and an average price target of $39.33. Other institutional investors like Opaleye Management Inc., EcoR1 Capital LLC, Vanguard Group Inc., Geode Capital Management LLC, and Divisadero Street Capital Management LP also adjusted their positions in Eton Pharmaceuticals.

News on $ETON

All news →